Healthcare Professionals
Hancock™ II bioprosthesis
The HancockTM II bioprostheses are for patients who require replacement of their native or prosthetic aortic and/or mitral valves.
The Hancock™ II valve has stood the test of time. First introduced in the 1980s, it has been tested and studied, and earned the trust of cardiac surgeons around the world. After dozens of years of clinical experience and improvements along the way, Hancock II has demonstrated strong performance and durability in both aortic and mitral valve patients.1,2
More than 40 years of delivering consistent performance and results
With Hancock™ II, you can feel confident procedure after procedure.
- A large, prospective study enrolling 1,134 SAVR patients (mean age of 67) from 1982 to 2004 showed:†,1
- Freedom from reoperation due to structural valve deterioration (SVD) in the full cohort at 20 years was 68.2%
- Freedom from SVD at 20 years in patients over the age of 65 was 97.8%
- The authors conclude: “Hancock™ II bioprosthesis is a very durable valve in patients 60 years and older and is probably the gold standard of bioprosthetic valve durability in this patient population.”
- A 3-center study including 484 mitral valve replacement patients (mean age 65.8) from 1983 to 2002 with Hancock™ II showed:2
- 71% Freedom from reoperation at 15 years
- Freedom from SVD in patients 60 years and older was 88% at 15 years
- The authors conclude: “Optimal 15-year durability can be expected... in male patients 65 years and older who have undergone mitral valve replacement.”2
Durability
Published clinical experience demonstrates impressive long-term performance in many SAVR age groups for both the aortic and mitral valve.1–3 Additional factors that may contribute to durability are:
- T6 (sodium dodecyl sulfate) anti-calcification treatment applied to reduce the absorption of calcium in the leaflets4–6
- Two-step, low-pressure fixation process
Ease of implant
Our innovative Cinch™ implant system further capitalizes on the valve’s flexible stent to facilitate valve implantation, particularly through a tight sinotubular space. It also:
- Improves overall visualization
- Has stent posts that deflect to allow for easier knot tying near the posts in aortic replacements
- Helps prevent suture looping
- Facilitates minimally invasive procedures
- Protects tissue from inadvertent damage
Improved flow
The Hancock™ II valve is designed to allow the maximum amount of blood to flow through it.7
The sewing ring is mounted flush with the inflow edge of the scalloped stent allowing the bioprosthesis to be positioned completely superior to the annulus.
The internal diameter of the valve aligns with the patient’s annulus allowing for a larger available flow area.
The valve design allows blood to flow through the annulus — encountering only tissue, not obstructive components such as the stent and sewing ring.
Suitable for future interventions
Valve dimensions and geometry enable future valve-in-valve (ViV) replacements.
- Radiopaque annulus ring and stent post markers provide visible, distinct guidelines during ViV procedures.
- Enabled MR Conditional, with nonmetallic frame that mitigates risk of corrosion between SAV and TAV stent materials.
- Interior-mounted leaflets mitigate potential risk of coronary obstruction.8
Adverse events potentially associated with the use of bioprosthetic heart valves include: allergic reaction, angina, aortic tissue damage, cardiac dysrhythmias, embolism, endocarditis, heart failure, hemolysis, hemolytic anemia, hemorrhage, anticoag/antiplatelet related; inflammatory reaction; infection other than endocarditis; leak, transvalvular or paravalvular; mitral tissue damage; MI; NSVD; pleural effusion; prosthesis regurg; prosthesis stenosis; stroke; SVD; tamponade; valve thrombosis.
Product specifications
Hancock™ II Aortic Valve, Model T505
| Item number |
Valve size (stent OD‡) (± 0.5 mm) | Orifice diameter (stent ID) (± 0.5 mm) | Suture ring diameter (± 1 mm) | Valve height (± 0.5 mm) | Aortic protrusion (± 0.5 mm) |
|---|---|---|---|---|---|
| (A) | (B) | (C) | (D) | (E) | |
| T505C221 | 21 | 18.5 | 27.0 | 15.0 | 12.0 |
| T505C223 | 23 | 20.5 | 30.0 | 16.0 | 13.5 |
| T505C225 | 25 | 22.5 | 33.0 | 17.5 | 15.0 |
| T505C227 | 27 | 24.0 | 36.0 | 18.5 | 15.5 |
| T505C229 | 29 | 26.0 | 39.0 | 20.0 | 16.0 |
‡ Equivalent to annulus diameter.
Hancock II Ultra™ aortic valve, Model T510
 |
| Item number |
Valve size (stent OD‡) (± 0.5 mm) | Orifice diameter (stent ID) (± 0.5 mm) | Suture ring diameter (± 1 mm) | Valve height (± 0.5 mm) | Aortic protrusion (± 0.5 mm) |
|---|---|---|---|---|---|
| (A) | (B) | (C) | (D) | (E) | |
| T510C25 | 25 | 22.5 | 33.0 | 18.0 | 13.5 |
| T510C27 | 27 | 24.0 | 35.0 | 19.0 | 14.0 |
| T510C29 | 29 | 26.0 | 38.0 | 20.5 | 15.5 |
| T510C31 | 31 | 28.0 | 41.0 | 22.0 | 17.0 |
| T510C33 | 33 | 30.0 | 43.0 | 23.0 | 17.5 |
‡ Equivalent to annulus diameter.
Hancock™ II Ultra™ Aortic Valve, Model T505
| Order Number |
Valve Size (Stent O.D.‡ (±0.5 mm) |
Orifice Diameter (Stent O.D. (±0.5 mm) |
Suture Ring Diameter (±1 mm) |
Valve Height (±0.5 mm) |
Aortic Protrusion (±0.5 mm) |
|---|---|---|---|---|---|
| (A) | (B) | (C) | (D) | (E) | |
| T505U221 | 21 | 18.5 | 26.0 | 15.0 | 12.0 |
| T505U223 | 23 | 20.5 | 28.0 | 16.0 | 13.5 |
| T505U225 | 25 | 22.5 | 30.0 | 17.5 | 15.0 |
| T505U227 | 27 | 24.0 | 32.0 | 18.5 | 15.5 |
| T505U229 | 29 | 26.0 | 34.0 | 20.0 | 16.0 |
Hancock™ II bioprosthesis accessories
| Order Number | Description |
|---|---|
| T7610HKA | Tray, Accessory, Hancock II, Aortic |
| T7605HKM | Tray, Accessory, Hancock II, Mitral |
| T7505UX | Tray, Accessory, Hancock II Ultra, Supra-X Aortic Sizer Set |
| 7505UX | Hancock II Ultra, Supra-X Aortic Sizer Set |
| 7639 | Handle (234 mm length) pilant, without locknut handle to be used with Hancock II, Hancock II Ultra prostheses |
| 7639XL | Handle (368 mm length) pilant, without locknut handle to be used with Hancock II, Hancock II Ultra prostheses |
| 7505SET | Hancock II Aortic Obturator Set (no handles, no tray) |
| 7510SET | Hancock II Mitral Obturator Set (no handles, no tray) |
† For patients over age 65.
‡ Equivalent to annulus diameter.
References
1
David T, Armstrong S, Maganti M. Hancock II bioprosthesis for aortic valve replacement: the gold standard of bioprosthetic valves durability? The Annals of thoracic surgery. 2010;90(3):775–781. doi:10.1016/j.athoracsur.2010.05.034
2
Rizzoli G, Mirone S, Ius P, et al. Fifteen-year results with the Hancock II valve: A multicenter experience. Journal of Thoracic and Cardiovascular Surgery. 2006;132(3). doi:10.1016/j.jtcvs.2006.05.031
3
Une D, Ruel M, David T. Twenty-year durability of the aortic Hancock II bioprosthesis in young patients: is it durable enough?. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2014;46(5):825–830. doi:10.1093/ejcts/ezu014
4
Valfre C, Rizzoli G, Zussa C, et al. Clinical results of Hancock II versus Hancock Standard at long-term follow-up. The Journal of thoracic and cardiovascular surgery. 2006;132(3):595–601, 601.e1-2. doi:10.1016/j.jtcvs.2006.03.062
5
Butany J, Leong SW, Cunningham KS, D’Cruz G, Carmichael K, Yau TM. A 10-year comparison of explanted Hancock-II and Carpentier-Edwards supraannular bioprostheses. Cardiovasc Pathol. 2007;16(1):4–13.
6
Rodriguez-Gabella T, Voisine P, Puri R, et al. Aortic bioprosthetic valve durability: incidence, mechanisms, predictors, and management of surgical and transcatheter valve degeneration. Published online 2017. http://www.onlinejacc.org/content/70/8/101
7
Gallucci V. Cardiac Bioprostheses: Proceedings of the Second International Symposium. Elsevier Science & Technology Books; 1982.
8
Ribeiro H, Rodes-Cabau J, Blanke P, et al. Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry. European heart journal. 2018;39(8):687–695. doi:10.1093/eurheartj/ehx455